Vischer with Swiss Nuclides in closing of first batch of series A financing
Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors.
Vischer has been acting as legal counsel to Swiss Nuclides in this financing, with a team comprised of Matthias Staehelin (lead, pictured) and Dania Salvisberg.
The proceeds will be used to continue the preclinical and clinical develop of its lead molecules for prostate cancer, neuroendocrine tumours, and immunotherapy selection. Swiss Nuclides is developing the Pet tracers on a novel radionuclide production platform which enables the broad availability of these tracers while keeping the radiation burden on the patient to a minimum.
